Monopar Therapeutics (MNPR) Profit After Tax (2017 - 2026)

Monopar Therapeutics has reported Profit After Tax for 9 years, with the latest figure at -$3.5 million in Q3 2025.

• Quarterly Profit After Tax fell 168.61% year-over-year to -$3.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$9.9 million (down 49.39% YoY) and the FY2025 annual result came in at -$13.7 million, up 11.45% from the prior year.
• Profit After Tax declined to -$3.5 million in Q3 2025 per MNPR's latest filing, from -$2.5 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$57.0 in Q2 2021 and troughed at -$3.5 million in Q3 2025.
• A 5-year average of -$2.2 million and a median of -$2.4 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2021 and 2022: Profit After Tax surged 100.0% in 2021, then plunged 4847147.37% in 2022.
• Over 5 years, Profit After Tax stood at -$2.7 million in 2021, then dropped by 7.68% to -$2.9 million in 2022, then jumped by 32.15% to -$2.0 million in 2023, then soared by 33.35% to -$1.3 million in 2024, then tumbled by 168.61% to -$3.5 million in 2025.
• According to Business Quant data, Profit After Tax over the past three periods registered -$3.5 million, -$2.5 million, and -$2.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.